|1.||Moessler, Herbert: 17 articles (01/2016 - 09/2003)|
|2.||Moessler, H: 16 articles (08/2011 - 09/2001)|
|3.||Windisch, M: 12 articles (07/2006 - 01/2000)|
|4.||Doppler, Edith: 9 articles (01/2016 - 10/2008)|
|5.||Sharma, Aruna: 9 articles (10/2015 - 01/2010)|
|6.||Rockenstein, Edward: 9 articles (07/2015 - 05/2006)|
|7.||Adame, Anthony: 9 articles (07/2015 - 05/2006)|
|8.||Masliah, Eliezer: 9 articles (07/2015 - 05/2006)|
|9.||Mante, Michael: 8 articles (07/2015 - 05/2006)|
|10.||Sharma, Hari Shanker: 8 articles (01/2014 - 01/2010)|
01/01/2010 - "High-quality and large-scale randomised controlled trials may help to gain a better understanding of the potential value of cerebrolysin in acute ischaemic stroke."
11/15/2010 - "However, treatment with Cerebrolysin at a dose of 2.5 ml/kg initiated at 24 and 48 hr did not significantly reduce infarct volume but substantially improved neurological outcomes measured by an array of behavioral tests 21 and 28 days after stroke. "
01/01/2006 - "The significant improvement of NIHSS score was observed on day 28 (p<0,05) in patients treated with cerebrolysin within the first 3h after stroke onset comparing to those treated within 6-12h. "
07/01/2010 - "Cerebrolysin is effective for the treatment of Broca's aphasics with a first acute ischemic stroke of the left MCA territory."
01/01/2007 - "These results suggest that Cerebrolysin may be a useful treatment for enhancing neurological recovery after stroke."
|2.||Alzheimer Disease (Alzheimer's Disease)
01/01/2000 - "Our data suggests, that Cerebrolysin is a safe and effective treatment for Alzheimer's disease and that repeat treatments may maintain function in patients over the long-term."
01/01/2011 - "This subgroup analysis assessed safety and efficacy of Cerebrolysin in patients with moderate to moderately severe Alzheimer's disease (AD) (ITT data set: N = 133; MMSE: 14-20) included in a dose-finding study (ITT data set: N = 51; MMSE: 14-25). "
01/01/2007 - "Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease."
11/01/2003 - "The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance."
01/01/1994 - "Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT)."
04/01/2012 - "This paper reviews the clinical efficacy of Cerebrolysin in the treatment of dementia. "
04/01/2012 - "The results of these trials have shown statistically significant and clinically relevant treatment effects of Cerebrolysin on cognitive, global and functional domains in mild to moderately severe stages of dementia. "
01/01/1997 - "In the present study patients suffering from dementia were treated with an infusion therapy using the neurotrophic drug Cerebrolysin. "
04/15/2015 - "Cerebrolysin has a favorable adverse effect profile, and several meta-analyses have suggested that Cerebrolysin is beneficial as a dementia treatment. "
03/01/2010 - "Spotlight on cerebrolysin in dementia."
|4.||Brain Injuries (Brain Injury)
09/01/2003 - "A significant improvement in the patients' clinical outcome, only evident during the first year after brain trauma, was also found following Cerebrolysin infusions. "
01/01/2014 - "To assess the efficacy of cerebrolysin in patients with cranial/brain injury of moderate severity. "
04/15/2015 - "Cerebrolysin Asian Pacific trial in acute brain injury and neurorecovery: design and methods."
12/01/2013 - "The purpose of this study was to investigate how Cerebrolysin therapy enhances cognitive recovery for mild traumatic brain injury patients using a double-blinded, placebo-controlled, randomized phase II pilot study. "
12/01/2013 - "Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study."
|5.||Brain Ischemia (Cerebral Ischemia)
01/01/2014 - "To study the efficacy of cerebrolysin in 300 patients with chronic brain ischemia (CBI), I and II stages. "
04/01/1998 - "Open field tests were made on 489 white male rats to distinguish subgroups by baseline higher nervous activity (HNA) to study the effects of cerebrolysin (EBEVE, Austria) on relationships between neuronal activity and cerebral blood supply in normal cerebral circulation (CC) and in acute brain ischemia. "
07/01/2006 - "Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window."
01/01/2005 - "[The effect of cerebrolysin on the clinical symptoms and the course of ischemic encephalopathy]."
04/01/1998 - "In stable circulation, this was compensated due to cerebral metabolic reserve, but in intensive EEG activation, recorded by CC/EEG index, cerebrolysin reduces cerebral blood supply aggravating acute brain ischemia."
|3.||Tissue Plasminogen Activator (Alteplase)
|5.||Glycyrrhizic Acid (Glycyrrhizin)
|6.||Risperidone (Risperdal Consta)
|8.||Nerve Growth Factor (NGF)
|10.||Valproic Acid (Valproate, Semisodium)
|2.||Activities of Daily Living (ADL)